Company Announcements

Artiva Biotherapeutics prices IPO at $167 million

Source: RNS
RNS Number : 3014X
RTW Biotech Opportunities Ltd
22 July 2024
 

A green logo on a black background Description automatically generated

LEI: 549300Q7EXQQH6KF7Z84

22 July 2024

RTW Biotech Opportunities Ltd

Portfolio Company Update: Artiva Biotherapeutics prices IPO at $167 million

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Artiva Biotherapeutics ("Artiva") regarding its pricing of a $116 million initial public offering ("IPO"). Artiva will trade on Nasdaq Global Market under the ticker "ARTV".

Artiva's IPO raised $167 million by offering 13,920,000 shares at $12.00 per share. The shares finished flat on the first day of trading. As at 30 June 2024, Artiva represented 0.13% of the Company's NAV.

Artiva is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The Company initially invested in Artiva's Series B round in February 2021. 

Chris Liu, PhD, Senior Research Analyst at the Investment Manager said, "Artiva Biotherapeutics is diligently advancing its lead allogeneic natural killer (NK) cell therapy, AlloNK, through several clinical trials. Currently, AlloNK is undergoing a phase 1 trial for lupus nephritis and participating in a basket study across various autoimmune indications. The recent IPO underscores the significant potential impact of this groundbreaking therapy."

The full text of Artiva's announcement can be accessed on its website at: https://artivabio.com/.

 For Further Information

RTW Investments, LP

+44 20 7959 6361

Woody Stileman, Managing Director, Business Development

 

Krisha McCune, Director, Investor Relations

biotechopportunities@rtwfunds.com

 

Buchanan (PR & Communications Adviser)

 

+44 20 7466 5107

 

Charles Ryland

 

 

Henry Wilson

 

 

George Beale

 

 

Deutsche Numis (Joint Corporate Broker)

 

+44 20 7260 1000

 

Freddie Barnfield

 

 

Nathan Brown

 

Euan Brown

 

BofA Securities (Joint Corporate Broker)

+44 20 7628 1000

Edward Peel

 

Alex Penney

 

Cadarn Capital (Distribution & IR Partner)

 +44 73 6888 3211

David Harris

 

Elysium Fund Management Limited

 

Joanna Duquemin Nicolle, Chief Executive Officer

 

Sadie Morrison, Managing Director

 

 +44 14 8181 0100

Morgan Stanley Fund Services USA LLC

+1 914 225 8885

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

***********

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBLLFLZDLZBBB